Exhibitors Search
Andante FM
Booth no.
C60
| Exhibition | PARTNERING |
|---|---|
| Country | Korea, South |
| Address | 15-1 Achasan-ro 7-gil, Seongdong-gu, Seoul, Republic of Korea |
| Tel (Rep.) | 010-9985-6940 |
| Website | http://www.andantefm.co.kr |
Company Introduction
o Company Name : Andante FM (First Mover)
o Founded : March 2022 and invested by Korea University Holdings
o Location : JJ building 3064, Seongsu-dong 2-ga , Seongdong-gu, Seoul, South Korea
o Vision : Contribute to human health by developing new drugs targeting incurable diseases
o CEO : Young Do Yoo, PhD
- Professor of Korea University College of Medicine (’05.03-’25.02)
- Emeritus professor of Korea University College of Medicine
- CEO of Andante FM
o Homepage : www.andantefm.co.kr
o Founded : March 2022 and invested by Korea University Holdings
o Location : JJ building 3064, Seongsu-dong 2-ga , Seongdong-gu, Seoul, South Korea
o Vision : Contribute to human health by developing new drugs targeting incurable diseases
o CEO : Young Do Yoo, PhD
- Professor of Korea University College of Medicine (’05.03-’25.02)
- Emeritus professor of Korea University College of Medicine
- CEO of Andante FM
o Homepage : www.andantefm.co.kr
Promotional video
Exhibit Item
1. Development of peptide antibiotics using peptide platform technology to control gram-negative bacteria and multidrug-resistant bacteria (Novel MoA, First in Class), 1) Peptide Antibiotics (IV for Sepsis) : ADT-340, 117 or 337, 2) Peptide Antibiotics (for Skin Treatment) : ADT-340 or 338 ; 2. MRSA Diagnosis : Rapid diagnostic technology by capturing multidrug-resistant staphylococcus (SA, MRSA, VRSA) from blood and using qPCR (within 2 hours) : ADT-607
Exhibit Item Images
-
Product Name : 1) Peptide Antibiotics to control gram-negative bacteria and MDR bacteria 2) Rapid diagnostic technology by capturing MRSA from blood and qPCR1) Development of peptide antibiotics using peptide platform technology to control gram-negative bacteria and multidrug-resistant bacteria 2) Rapid diagnostic technology by capturing multidrug-resistant staphylococcus (SA, MRSA, VRSA) from blood and using qPCR (within 2 hours)
Exhibit Description
Unmet medical needs and First in Class
1. Peptide Antibiotics (IV): ADT-340, ADT-117 or ADT-337
2. Peptide Antibiotics for Skin Treatment: ADT-340 or 338
3. MRSA Diagnosis (MRSA capture by magnetic bead-peptide and qPCR)
4. PDC(Peptide-drug Conjugates for Cancer Treatment)
: Cancer cell-targeting peptide development, early studies
1. Peptide Antibiotics (IV): ADT-340, ADT-117 or ADT-337
2. Peptide Antibiotics for Skin Treatment: ADT-340 or 338
3. MRSA Diagnosis (MRSA capture by magnetic bead-peptide and qPCR)
4. PDC(Peptide-drug Conjugates for Cancer Treatment)
: Cancer cell-targeting peptide development, early studies
Co-Exhibitor or
Partner’s Information
| Company Name | Country |
|---|---|
KYUNGYON EXHIBITION CORP.